Skip Navigation

Cardiovascular Research 2004 64(3):395-401; doi:10.1016/j.cardiores.2004.09.003
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Regula, K. M.
Right arrow Articles by Kirshenbaum, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Regula, K. M.
Right arrow Articles by Kirshenbaum, L. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Therapeutic opportunities for cell cycle re-entry and cardiac regeneration

Kelly M. Regula, Marek J. Rzeszutek, Delphine Baetz, Charit Seneviratne and Lorrie A. Kirshenbaum*

The Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, and the Department of Physiology, Faculty of Medicine, University of Manitoba, Rm. 3016, 351 Taché Avenue, Winnipeg, Manitoba, R2H 2A6, Canada

* Corresponding author. Tel.: +1 204 235 3661; fax: +1 204 233 6723. Email address: lorrie{at}sbrc.ca

Over the last two decades, considerable effort has been made to better understand putative regulators and molecular switches that govern the cell cycle in attempts to reactivate cell cycle progression of cardiac muscle. Rapid advancements on the field of stem cycle biology including evidence of cardiac progenitors within the adult myocardium itself and reports of cardiomyocyte DNA synthesis, which each suggest that the adult myocardium may in fact have the capacity for de novo myocyte regeneration. Augmenting cardiomyocyte number by targeting specific cell cycle regulatory genes or by stimulating cardiac progenitor cells to differentiate into cardiac muscle may be of therapeutic value in repopulating the adult myocardium with functionally active cells in patients with end-stage heart failure. Advancements in the area of cardiomyocyte cell cycle control and regeneration and their therapeutic potential are discussed.

KEYWORDS Cell cycle; DNA synthesis; Ventricular myocytes; Regeneration

Time for primary review 20 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ICVTSHome page
R. Gabel, C. Klopsch, D. Furlani, C. Yerebakan, W. Li, M. Ugurlucan, N. Ma, and G. Steinhoff
Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats
Interactive CardioVascular and Thoracic Surgery, July 1, 2009; 9(1): 20 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. Tamamori-Adachi, H. Takagi, K. Hashimoto, K. Goto, T. Hidaka, U. Koshimizu, K. Yamada, I. Goto, Y. Maejima, M. Isobe, et al.
Cardiomyocyte proliferation and protection against post-myocardial infarction heart failure by cyclin D1 and Skp2 ubiquitin ligase
Cardiovasc Res, November 1, 2008; 80(2): 181 - 190.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.